Improved tools are needed to efficiently "knock out" genes and "knock in" targeted genome modifications to modulate T-cell function and correct disease-associated mutations. CRISPR/Cas9 technology is facilitating genome engineering in many cell types, but in human T cells its efficiency has been limited and it has not yet proven useful for targeted nucleotide replacements. Here we report efficient genome engineering in human CD4
+ T cells using Cas9:single-guide RNA ribonucleoproteins (Cas9 RNPs). Cas9 RNPs allowed ablation of CXCR4, a coreceptor for HIV entry. Cas9 RNP electroporation caused up to ∼40% of cells to lose high-level cell-surface expression of CXCR4, and edited cells could be enriched by sorting based on low CXCR4 expression. Importantly, Cas9
RNPs paired with homology-directed repair template oligonucleotides generated a high frequency of targeted genome modifications in primary T cells. Targeted nucleotide replacement was achieved in CXCR4 and PD-1 (PDCD1), a regulator of T-cell exhaustion that is a validated target for tumor immunotherapy. Deep sequencing of a target site confirmed that Cas9 RNPs generated knock-in genome modifications with up to ∼20% efficiency, which accounted for up to approximately one-third of total editing events. These results establish Cas9 RNP technology for diverse experimental and therapeutic genome engineering applications in primary human T cells.
CRISPR/Cas9 | genome engineering | Cas9 ribonucleoprotein | RNP | primary human T cells T he CRISPR/Cas9 system has been used increasingly to edit mammalian germline sequence and cell lines (1, 2) . Considerable efforts are underway to use this powerful system directly in primary human tissues, but efficiency has been limited, especially in human CD4 + T cells. Plasmid delivery of cas9 and single-guide RNAs (sgRNAs) was efficient in other cell types, but ablated only 1-5% of target protein expression in CD4 + T cells (3) . Improved ability to ablate key targets and correct pathogenic genome sequence in human T cells would have direct therapeutic applications, eventually allowing T cells to be edited ex vivo and then reintroduced into patients.
Multiple scientific and clinical trials are underway to manipulate T-cell genomes with available technologies, including gene deletions with transcription activator-like effector nucleases and zinc finger nucleases and exogenous gene introduction by viral transduction (4, 5) . Genetic manipulations have been attempted to "knock out" HIV coreceptors CXCR4 and CCR5 in T cells to gain resistance to HIV infection (6) (7) (8) . There also has been marked success in engineering T cells to recognize and kill hematological malignancies, but additional genetic modifications appear necessary for solid organ tumor immunotherapy (9) (10) (11) . Deletion of genes that encode key immune checkpoints such as PD-1 could prove useful for these efforts (12, 13) . Further therapeutic opportunities would be possible if targeted T-cell genomic loci could be corrected with specific replacement sequence, rather than deleted (14) . Efficient technology to promote homologous recombination in T cells could eventually allow therapeutic correction of mutations that affect specialized T-cell functions.
Recent reports in mammalian cell lines demonstrate that Cas9 ribonucleoproteins (RNPs; recombinant Cas9 protein complexed with an in vitro-transcribed single-guide RNA) can accomplish efficient and specific genome editing (15) (16) (17) . Here we show that electroporation of Cas9 RNPs leads to efficient genome editing of CD4 + T cells. We were able to ablate a target gene with the random insertion and deletion mutations that likely result from nonhomologous end joining (NHEJ) repair of a Cas9-induced double-stranded DNA break (DSB). Cells with genomic edits in CXCR4 could be enriched by sorting based on low CXCR4 expression. We were also able to introduce precisely targeted nucleotide replacements in primary T cells at CXCR4 and PD-1 by homology-directed repair (HDR) using Cas9 RNPs and exogenous single-stranded DNA templates. This technology enabled Cas9-mediated generation of "knock-in" primary human T cells. Deep sequencing of a target site confirmed that Cas9 RNPs promoted knock-in Significance T-cell genome engineering holds great promise for cancer immunotherapies and cell-based therapies for HIV, primary immune deficiencies, and autoimmune diseases, but genetic manipulation of human T cells has been inefficient. We now have achieved Q:10 efficient genome editing by delivering Cas9 protein pre-assembled with guide RNAs. These active Cas9 ribonucleoproteins (RNPs) enabled successful Cas9-mediated homology-directed repair in primary human T cells. Cas9 RNPs provide a programmable tool to replace specific nucleotide sequences in the genome of mature immune cells-a longstanding goal in the field. These studies establish Cas9 RNP technology for diverse experimental and therapeutic genome engineering applications in primary human T cells.
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genome modifications with up to ∼20% efficiency (∼22% was achieved with 50 pmol and ∼18% with 100 pmol of HDR template), which accounted for up to approximately one-third of the total editing events. These findings suggest that Cas9 RNP-mediated nucleotide replacement could eventually prove useful for therapeutic correction of disease-associated mutations. Our study establishes Cas9 RNP technology for experimental and therapeutic knock-out and knock-in editing of the genome in primary human T cells.
Results
We aimed to overcome long-standing challenges in genetic manipulation of primary T cells and establish an efficient genome engineering toolkit. Recent reports in mammalian cell lines suggest that Cas9 RNPs can accomplish efficient and specific genome editing (15) (16) (17) (18) . Given the significant challenges of efficient genome editing of T cells with DNA delivery of Cas9, we tested the efficacy of Cas9 RNP delivery for targeted genome editing in primary human T cells (Fig. 1A) .
Ablation of HIV Coreceptor CXCR4 with Cas9 RNPs. A major goal in T-cell engineering is targeted ablation of specific cell-surface receptors, including coreceptors for HIV infection and coinhibitory immune checkpoints that impair tumor immune response. Here, we programmed the Cas9 RNPs to target the exonic sequence of CXCR4, which encodes a chemokine receptor with multiple roles in hematopoiesis and cell homing that is expressed on CD4
+ T cells and serves as a coreceptor for HIV entry (19) (20) (21) . We purified recombinant Streptococcus pyogenes Cas9 carrying two nuclear localization signal sequences fused at the C terminus. This Cas9 protein was incubated with in vitro-transcribed sgRNA designed to uniquely recognize the human CXCR4 genomic sequence (Fig. 1B) . These preassembled Cas9 RNP complexes were electroporated into human CD4
+ T cells isolated from healthy donors. Electroporation of CXCR4 Cas9 RNPs caused efficient, sitespecific editing of genomic DNA. The Cas9 RNP-induced DSBs in the CXCR4 gene were likely repaired by NHEJ, a predominant DNA repair pathway in cells that gives rise to variable insertions and deletions (indels) and often results in frameshift mutations and loss of gene function (22) . Flow cytometry revealed a Cas9 RNP dose-dependent increase in the percentage of T cells expressing low levels of CXCR4, consistent with mutation of the CXCR4 gene (Fig. 1C) . The T7 endonuclease 1 (T7E1) assay is a convenient method to assess editing at specific sites in the genome. Here, T7E1 assay confirmed genomic DNA editing at the CXCR4 locus in cells treated with CXCR4 Cas9 RNPs, but not in control cells treated with Cas9 protein alone (no sgRNA; CTRL). Cas9 RNP-treated cells were separated based on CXCR4 expression with fluorescence-activated cell sorting (FACS). Using the T7E1 assay, we found an enrichment of editing in the CXCR4 lo cells (15-17%) compared with CXCR4 hi cells (4-12% with varying doses of Cas9 RNP) (Fig. 1D) . Sanger sequencing of the target CXCR4 genomic site, performed to directly identify editing events, suggested that the T7E1 assay may have underestimated editing efficiency. The T7E1 assay uses denaturation and hybridization of the wild-type and mutant sequences to create a mismatch DNA duplex, which is then digested by T7 endonuclease. However, hybridization of the mismatch duplex may be inefficient, especially when the indel mutation is drastically different from the wild-type sequence, making selfhybridization an energetically more favorable product. Other potential reasons for observed underestimation of editing efficiency with endonuclease assays include incomplete duplex melting, inefficient cleavage of single-base-pair indels, and deviation from the expected 300-and 600-bp products on the agarose gel as a result of large genome edits (23) . Sequencing of the CXCR4 gene in CXCR4 lo cells showed that 5/6 clones had mutations/deletions whereas such mutations/deletions were observed in only 4/10 clones and 0/9 clones in CXCR4 hi and CTRL-treated CXCR4 lo cells, respectively. Importantly, none of the observed edits in the CXCR4 hi population terminated the coding sequence (one missense mutation and three in-frame deletions), consistent with the maintenance of protein expression. By contrast, the CXCR4 lo population was enriched for cells with a more extensive mutational burden in the locus (Fig. 1E) . These findings demonstrated successful genomic targeting with Cas9 RNPs and a functional effect on protein expression in human CD4 + T cells. Importantly, FACS was able to enrich the population of edited cells, providing an additional useful tool for Cas9 RNP applications in primary T cells.
Efficient Genetic Knock-In with Homology-Directed Repair. Exogenous template-mediated HDR is a powerful technique for precise gene modifications that would enable experimental and therapeutic editing of specific variant sequences. Given the high editing efficiency of Cas9 RNPs, we next tested whether we could achieve exogenous template-mediated HDR in primary T cells. We used a single-stranded oligonucleotide DNA template (HDR template) with 90 nucleotide homology arms to recombine with the CXCR4 locus at the Cas9 RNP cleavage site (16) . The CXCR4 HDR template was designed to replace 12 nucleotides from the human reference genome, including the protospacer adjacent motif (PAM) sequence required for CRISPR-mediated DNA cleavage, and to introduce a HindIII restriction enzyme cleavage site ( Fig. 2A) (Fig. S1A) . In the experiment shown here, ∼60% of cells lost high-level cell-surface CXCR4 expression with 100 pmol HDR template and Cas9 RNP (1 vs. 60% in control-treated cells) ( Fig. 2 B and C) .
Remarkably efficient HDR was observed in cells treated with Cas9 RNP and the single-stranded oligonucleotide HDR template (Fig. 2D ). Up to 33% total editing (defined as the sum of all NHEJ and HDR events that give rise to indels at Cas9 cleavage site) was observed in the presence of 50 pmol CXCR4 HDR template, as estimated by T7E1 assays. At this concentration, 14% HDR was estimated by HindIII digest of the target locus, indicating that a high fraction of editing resulted from HDR (see results below for further quantification). The nearly complete loss of CXCR4 staining with addition of the HDR template suggests that the mutation introduced by HDR (84DLLFV88 → 84ESLDP88) strongly affected the cell-surface expression of CXCR4 or its recognition by the antibody (Fig. 2 B and C) . The editing efficiency was reduced with 200 pmol HDR template, perhaps as a result of cellular toxicity.
Both total editing and HDR could be enriched by sorting the CXCR4 lo population, although the effect was less pronounced than in Fig. 1 , consistent with the larger fraction of CXCR4 lo cells in the unsorted population. Note that in these experiments a more stringent gate was applied to separate the cells with the highest expression of CXCR4, and in this CXCR4 hi population no editing was observed. These studies collectively demonstrated the power of Cas9 RNPs coupled with single-stranded oligonucleotide HDR template to precisely replace targeted DNA sequences in primary human T cells.
Deep Sequencing of Target Genomic DNA. Deep sequencing of the targeted CXCR4 locus allowed more detailed and quantitative analysis of genome-editing events. The results highlighted in Fig. 3 show the frequency of insertions, deletions, and HDRmediated nucleotide replacement in CXCR4 Cas9 RNP-treated cells with or without CXCR4 HDR template compared with control-treated cells. In CXCR4 Cas9 RNP-treated cells, we found 55% of reads overlapping the CXCR4 target site containing at least one indel within a 200-nucleotide window centered around the expected cut site ( Fig. 3 A and B and Dataset S1). As discussed above, the T7E1 assays are useful for identifying edited loci, but may underestimate actual editing efficiency (quantitation of the T7E1 assay in show maximal ablation of CXCR4 with Cas9 RNP treatment and 100 pmol of HDR template. (D) T7E1 assay was used to estimate the "% Total Edit" (defined as the sum of all NHEJ and HDR events that gives rise to indels at the Cas9 cleavage site), whereas HDR frequency was determined by HindIII digestion, which specifically cleaved the newly integrated HindIII site, and was calculated as the ratio of DNA product to DNA substrate. Expected PCR product size (938 nt) and approximate expected T7E1 and HindIII digestion fragments are indicated.
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PNAS Early Edition | 3 of 6 249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310   311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330   338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371 compared with the 55% editing efficiency computed by deep sequencing). We also sequenced the two top predicted "offtarget" sites for the CXCR4 Cas9 RNP (Fig. 3B ). Rare indels were observed at both off-target sites (∼1-2%), but at a rate comparable to that observed for those sites in the control cells treated with Cas9 protein only (∼1-2%) (Dataset S1). The deep-sequencing results allowed quantitative analysis of observed indel mutations and their spatial distribution in the target region. Consistent with reports that S. pyogenes Cas9 cuts about three nucleotides upstream from the PAM sequence, we found the highest frequency of indels at four nucleotides upstream of the PAM (Fig. 3A) . Indels were distributed throughout the sequenced region ( Fig. 3 C and D) with the majority of events near cut sites (>94% within 40 nucleotides). In CXCR4 Cas9 RNP-treated cells within ±100 nucleotides from the cut site, we observed that 95% of reads with indels contained a deletion event whereas 10% contained an insertion event (Dataset S1). Interestingly, of the reads with insertion events, ∼50% also contained at least one deletion. We observed a wide range of insertion and deletion sizes, with many reads exhibiting deletions up to ∼80 nucleotides in length (mean: 18 nucleotides; SD: 15 nucleotides) and some insertions up to ∼55 nucleotides in length (mean: 4.4 nucleotides; SD: 4.8 nucleotides) ( the successful targeted replacement of 12 nt at the CXCR4 locus, but only in cells treated with both Cas9 RNPs and CXCR4 HDR template. We observed 25% incorporation of HDR template sequence with 50 pmol HDR template and 21% with 100 pmol HDR template (Fig. 3A) . Of the reads with HDR template sequence incorporated, ∼14% of the detected HDR template reads had additional nonspecific indels surrounding the incorporated HindIII site or other imperfect forms of editing within the 200-nucleotide window centered at the predicted cut site. However, the frequency of indels in reads with the HindIII site incorporated was reduced compared with reads where the HindIII site was not detected (Fig. 3 C and D and Fig. S2 ). Interestingly, there was a consistent pattern of deletion events between CXCR4 Cas9 RNP with and without CXCR4 HDR template with an enrichment of deletions of 2 nucleotides (11%) and 22 nucleotides (5.4%) (Fig. S2) . Replacement of the PAM sequence likely helped to limit recutting of knock-in sequence. Overall, 18-22% of reads (with varying concentrations of HDR template) had correctly replaced nucleotides throughout the sequenced genomic target site, suggesting that this approach could prove useful for generation of experimental and therapeutic nucleotide knock-in primary human T cells.
IMMUNOLOGY AND INFLAMMATION
Specific Knock-In Targeting of Key Cell-Surface Receptors. To confirm that Cas9 RNPs mediate HDR at other genomic sites, we designed a guide RNA and HDR template to target the PD-1 (PDCD1) locus. PD-1 is an "immune checkpoint" cell-surface receptor found on the surface of chronically activated or exhausted T cells that can inhibit effective T-cell-mediated clearance of cancers. Monoclonal antibody blockade of PD-1 is approved for treatment of advanced malignancy, and genetic deletion of PD-1 may prove useful in engineering T cells for cell-based cancer immunotherapies (12) . Primary human T cells were electroporated with a PD-1 Cas9 RNP and a PD-1 HDR template designed to generate a frameshift mutation and a knock-in a HindIII restriction site in the first exon of PD-1, thereby replacing the PAM sequence (Fig. 4A) .
To examine the specificity of Cas9 RNP-mediated targeting, we compared PD-1 cell-surface expression following treatment with PD-1 Cas9 RNP vs. CXCR4 Cas9 RNP (which should not target 373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434   435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495 the PD-1 locus) or scrambled guide Cas9 RNP (no predicted cut within the human genome). We performed replicate experiments side by side with two different blood donors and with sgRNAs generated with two different in vitro transcription protocols (SI Materials and Methods). PD-1 Cas9 RNPs electroporated with PD-1 HDR template significantly reduced the percentage of cells with high PD-1 cell-surface expression relative to both CXCR4 Cas9 RNPs and scrambled guide Cas9 RNPs delivered with PD-1 HDR template (Fig. 4B) . Similarly, CXCR4 Cas9 RNPs and CXCR4 HDR template caused a decrease in the CXCR4 hi cell population relative to both PD-1 and scrambled guide Cas9 RNP treatments with CXCR4 HDR template (Fig. 4C) . Loss of CXCR4 was not a nonspecific effect of single-stranded DNA delivered along with CXCR4 Cas9 RNP; we observed a higher percentage of CXCR4-expressing cells after treatment with CXCR4 Cas9 RNP and scrambled HDR template than with CXCR4 Cas9 RNP and CXCR4 HDR template (Fig. S1A) . These findings confirmed the target-specific modulation of cell-surface receptor expression in primary T cells with the programmable Cas9 RNP and HDR template treatments.
We then tested the specificity of HDR templates for nucleotide replacement ( Fig. 4D ; examples of corresponding cell-surface expression data are shown in Fig. S1B ). As expected, we observed efficient PD-1 editing by PD-1 Cas9 RNPs regardless of whether they were delivered with PD-1 HDR template, CXCR4 HDR template, or without any HDR template. In
contrast, the HindIII site was incorporated into PD-1 only in the presence of both PD-1 Cas9 RNP and PD-1 HDR template, but not with CXCR4 HDR template, which should not be recombined at PD-1 locus due to the lack of sequence homology. Similarly, a HindIII site was incorporated only into CXCR4 following treatment with CXCR4 Cas9 RNP and CXCR4 HDR template; HDR was not observed at the CXCR4 locus with PD-1 HDR template, control scrambled HDR template (with a HindIII site), or without HDR template (Fig. 4D) . Taken together, these studies established that specific pairing of a programmed Cas9 RNP and corresponding HDR template is required for targeted nucleotide replacement in primary human T cells.
Discussion
Cas9-mediated genome engineering has enormous potential to experimentally and therapeutically target DNA elements crucial for T-cell function. We report here successful genome engineering in human CD4
+ T cells by delivery of in vitro-assembled Cas9 RNPs. Electroporation of Cas9 RNPs allowed targeted knock-out of the CXCR4 cell-surface receptor. Cas9 RNPs also promoted successful Cas9-mediated genetic knock-in of specific nucleotides to CXCR4 and PD-1 in primary human T cells. The efficient targeted DNA replacement in mature immune cells achieves a longstanding goal in the immunology field to enable diverse research and therapeutic applications. These studies collectively establish a broadly applicable toolkit for genetic manipulation of human primary T cells.
There are notable advantages to genome engineering with transient Cas9 RNP delivery compared with other CRISPR/Cas9 delivery methods. Recent work reported ablation of cell-surface markers in human CD4
+ T cells by transfection of plasmid carrying the cas9 gene and guide RNA-coding sequence (3). Although successful, efficiency was notably low in CD4
+ T cells compared with other cell types, possibly due to suboptimal levels of Cas9 or sgRNA, suboptimal nuclear translocation, or suboptimal intracellular Cas9 RNP complex formation (or some combination of these factors). Cas9 RNP-based delivery circumvents these challenges. Delivery of Cas9 RNPs offers fast editing action and rapid protein turnover in the cells as they are reportedly degraded within 24 h of delivery (15) . This limited temporal window of Cas9 editing may make Cas9 RNPs safer for therapeutic applications than other 497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558   559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619 delivery modes where cells are exposed to Cas9 for a longer time frame. Further testing will be needed to assess the purity of Cas9 RNPs and potential off-target effects before any clinical use. Our findings now suggest that Cas9 RNPs are able to rapidly and efficiently edit human T cells. We were able to achieve remarkably efficient HDR here with almost complete loss of the CXCR4 hi cell population with Cas9 RNPs and an HDR template targeting CXCR4 in one experiment. Up to 25% of the reads showed incorporation of HDR template sequence in the CXCR4 locus, and ∼20% of the reads showed correctly replaced sequence throughout the target site with no additional indels. Future studies will optimize remaining variables that affect editing and HDR efficiency in primary T cells. We recently demonstrated in cultured cell lines that variation in cell type and cell cycle dynamics significantly alter Cas9 RNP efficiency (16) . In primary human T cells, editing efficiency could also be affected by T-cell donor-specific factors (e.g., genetics, recent infection), in vitro T-cell activation status, and characteristics of the targeted genomic locus (e.g., DNA sequence, chromatin state). Characterizing these variables and further optimizing genome engineering efficiency will accelerate the experimental and therapeutic editing of T cells using Cas9 RNPs.
The ability to edit specific DNA sequences in human T-cell subsets will enable experimental investigation of transcription factors, cis-regulatory elements, and target genes implicated in T-cell inflammatory and suppressive functions. Extensive efforts have mapped key gene regulatory circuitry controlling the development and function of diverse and specialized T-cell subsets (24) . We recently reported that most causal genetic variants contributing to risk of human autoimmune diseases map to key regulatory elements in T cells (25) . Looking forward, genome editing of primary T cells will now provide a powerful perturbation test to assess the function of regulatory elements and characterize the effects of disease-associated coding and noncoding variation.
Therapeutic editing requires improved techniques to identify successfully edited cells in a population. Selection of edited cells is notably challenging in primary cells that cannot be maintained indefinitely in culture, unlike transformed cell lines. Here we demonstrate FACS enrichment of edited cells based on expected phenotypic changes in cell-surface receptor expression. The success of Cas9 RNP-mediated HDR should also allow introduction of genetic markers to purify homogenously edited cells for further functional characterization and potentially also for therapeutic applications.
Therapeutic T-cell engineering requires efficient and precisely targeted genome editing in primary cells. The Cas9 RNP technology reported here should accelerate efforts to correct genetic variants and engineer human T-cell function for the treatment of infection, autoimmunity, and cancer. Analysis of Genome Editing. Editing efficiency was estimated by T7 endonuclease I assay. HDR templates were designed to introduce a HindIII restriction site into the targeted gene loci; successful HDR was confirmed with HindIII restriction enzyme digestion. The genomic region flanking the Cas9 target site for the CXCR4 on-target and two off-target genes was amplified by the two-step PCR method. Sequencing libraries were sequenced with the Illumina HiSEq. 2500.
Materials and Methods
See SI Materials and Methods for further details.
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SI Materials and Methods
Human T-Cell Isolation and Culture. Human primary T cells were isolated from either fresh whole blood or buffy coats (Stanford Blood Center). Whole blood was collected from human donors in sodium heparinized vacutainer tubes (Becton Dickinson) with approval by the UCSF Committee on Human Research and processed within 12 h. PBMCs were isolated by Ficoll gradient centrifugation. Fresh blood was mixed in a 1:1 ratio with Ca 2+ and Mg 2+ free HBSS, Buffy coats were diluted in a 1:10 ratio with HBSS. Thirty milliliters of the respective HBSS/blood solution were transferred to 50-mL Falcon tubes and underlaid with 12 mL Ficoll-Paque PLUS (Amersham/GE healthcare). After density gradient centrifugation (1,000 × g, 20 min, no brakes) the PBMC layer was carefully removed and the cells were washed twice with Ca 2+ and Mg 2+ free HBSS. CD4 + T cells were pre-enriched with a Easysep Human CD4 + T-cell enrichment kit (Stemcell Technologies) according to the manufacturer's protocol. Pre-enriched CD4 + T cells were stained with the following antibodies: αCD4-PerCp (SK3; Becton Dickinson), αCD25-APC (BC96; TONBO Biosciences), αCD127-PE (R34-34; TONBO Biosciences), αCD45RA-violetFluor450 (HI100; TONBO Biosciences), and αCD45RO-FITC (UCHL1; TONBO Biosciences). CD4
hi Teffs were isolated using a FACS Aria Illu (Becton Dickinson). Teff purity was >97%.
For Cas9 RNP transfections, the effector CD4 + T cells isolated from whole blood were preactivated on αCD3 (UCHT1; BD Pharmingen) and αCD28 (CD28.2; BD Pharmingen) coated plates for 48 h. Plates were coated with 10 μg/mL αCD3 and αCD28 in PBS for at least 2 h at 37°C. Buffy coat-derived T cells were activated on plates coated with 10 μg/mL αCD3 (in PBS for at least 2 h at 37°C) with 5 μg/mL αCD28 added directly to the RPMI complete medium.
The T cells were activated in RPMI complete, RPMI-1640 [UCSF Cell Culture Facility (CCF)] supplemented with 5 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes) (UCSF CCF), 2 mmol/L Glutamax (Gibco), 50 μg/mL penicillin/streptomycin (Corning), 50 μmol/L 2-mercaptoethanol (Sigma-Aldrich), 5 mmol/L nonessential amino acids (Corning), 5 mmol/L sodium pyruvate (UCSF CCF), and 10% FBS (Atlanta Biologicals). After electroporation the medium was supplemented with 40 IU/mL IL-2.
Expression and Purification of Cas9. The recombinant S. pyogenes Cas9 used in this study carries at the C terminus an HA tag and two nuclear localization signal peptides that facilitate transport across the nuclear membrane. The protein was expressed with a N-terminal hexahistidine tag and maltose binding protein in Escherichia coli Rosetta 2 cells (EMD Millipore) from plasmid pMJ915. The His tag and maltose-binding protein were cleaved by TEV protease, and Cas9 was purified by the protocols described in Jinek et al. (1) . Cas9 was stored in 20 mM Hepes at pH 7.5, 150 mM KCl, 10% glycerol, 1 mM TCEP at −80°C.
In Vitro T7 Transcription of sgRNA with PAGE Purification. The DNA template encoding for a T7 promoter, a 20-nt target sequence, and the chimeric sgRNA scaffold was assembled from synthetic oligonucleotides by overlapping PCR. Briefly, for the CXCR4 sgRNA template, the PCR contains 20 nM premix of SLKS3 (5′-TAA TAC GAC TCA CTA TAG GAA GCG TGA TGA CAA  AGA GGG TTT TAG AGC TAT GCT GGA AAC AGC ATA  GCA AGT TAA AAT AAG G -3′) and SLKS1 (5′-GCA CCG  ACT CGG TGC CAC TTT TTC AAG TTG ATA ACG GAC  TAG CCT TAT TTT AAC TTG CTA TGC TGT TTC CAG C-3′),  1 μM premix of T25 (5′-TAA TAC GAC TCA CTA TAG-3′) and   SLKS1 (5′-GCA CCG ACT CGG TGC CAC TTT TTC AAG-3′) , and 200 μM dNTP and Phusion Polymerase (NEB) according to the manufacturer's protocol. The thermocycler setting consisted of 30 cycles of 95°C for 10 s, 57°C for 10 s, and 72°C for 10 s The PCR product was extracted once with phenol:chloroform:isoamylalcohol and then once with chloroform before isopropanol precipitation overnight at −20°C. The DNA pellet was washed three times with 70% ethanol, dried by vacuum, and dissolved in DEPC Q:1 -treated water. The PD-1 sgRNA template was assembled from T25, SLKS1, SLKS2, and SLKS11 (5′-TAA TAC GAC TCA CTA TAG CGA CTG GCC AGG GCG CCT GTG TTT TAG AGC TAT GCT GGA AAC AGC ATA GCA AGT TAA AAT AAG G-3′) by the same procedure.
A 100-μL T7 in vitro transcription reaction consisted of 30 mM Tris·HCl (pH 8), 20 mM MgCl 2 , 0.01% Triton X-100, 2 mM spermidine, 10 mM fresh DTT, 5 mM of each ribonucleotide triphosphate, 100 μg/mL T7 Pol, and 0.1 μM DNA template. The reaction was incubated at 37°C for 4 h, and 5 units of RNase-free DNaseI (Promega) was added to digest the DNA template 37°C for 1 h. The reaction was quenched with 2× STOP solution (95% deionized formamide, 0.05% bromophenol blue, and 20 mM EDTA) at 60°C for 5 min. The RNA was purified by electrophoresis in 10% polyacrylamide gel containing 6 M urea. The RNA band was excised from the gel, ground up in a 50-mL tube, and eluted overnight in 25 mL of 300 mM sodium acetate (pH 5) overnight at 4°C with gentle rocking. The solution was then centrifuged at 4,000 × g for 10 min, and the RNA supernatant was passed through a 0.45-μm filter. One equivalent of isopropanol was added to the filtered supernatant to precipitate the RNA overnight at −20°C. The RNA pellet was collected by centrifugation, washed three times with 70% ethanol, and dried by vacuum. To refold the sgRNA, the RNA pellet was first dissolved in 20 mM Hepes (pH 7.5), 150 mM KCl, 10% glycerol, and 1 mM TCEP. The sgRNA was heated to 70°C for 5 min and cooled to room temperature. MgCl 2 was added to a final concentration of 1 mM. The sgRNA was again heated to 50°C for 5 min, cooled to room temperature, and kept on ice. The sgRNA concentration was determined by OD 260nm using Nanodrop and adjusted to 100 μM using 20 mM Hepes (pH 7.5), 150 mM KCl, 10% glycerol, 1 mM TCEP, and 1 mM MgCl 2 . The sgRNA was stored at −80°C.
In Vitro T7 Transcription of sgRNA with Phenol/Chloroform Extraction.
DNA templates for in vitro T7 transcription were generated by annealing complementing single-stranded ultramers (Ultramer  sequences: CXCR4_1: 5′-TAA TAC GAC TCA CTA TAG  GAA GCG TGA TGA CAA AGA GGG TTT TAG AGC TAT  GCT GGA AAC AGC ATA GCA AGT TAA AAT AA GGC  TAG TCC GTT ATC AAC TTG AAA AAG TGG CAC CGA  GTC GGT G-3′; CXCR4_2: 5′-CAC CGA CTC GGT GCC  ACT TTT TCA AGT TGA TAA CGG ACT AGC CTT ATT  TTA ACT TGC TAT GCT GTT TCC AGC ATA GCT CTA  AAA CCC TCT TTG TCA TCA CGC TTC CTA TAG TGA  GTC GTA TTA-3′; PD-1_1: 5′-TAA TAC GAC TCA CTA  TAG CGA CTG GCC AGG GCG CCT GTG TTT TAG AGC  TAT GCT GGA AAC AGC ATA GCA AGT TAA AAT AAG  GCT AGT CCG TTA TCA ACT TGA AAA AGT GGC ACC  GAG TCG GTG C-3′; PD-1_2: 5′-GCA CCG ACT CGG TGC  CAC TTT TTC AAG TTG ATA ACG GAC TAG CCT TAT  TTT AAC TTG CTA TGC TGT TTC CAG CAT AGC TCT  AAA ACA CAG GCG CCC TGG CCA GTC GCT ATA GTG  AGT CGT ATT A-3′) . Ultramers were mixed in a 1:1 ratio in nuclease-free duplex buffer (IDT) and heated up to 95°C for 2 min followed by a 30-min incubation at room temperature.
A 100-μL T7 in vitro transcription reaction contained 1× Transcription Optimized buffer (Promega), 10 mM fresh DTT, 2 mM of each ribonucleotide triphosphate, 400 U T7 Pol (Promega), 0.5 U pyrophosphatase (Life Technologies), and 2 μg DNA template. The reaction was incubated for 4 h at 37°C. Five units of RNase-free DNaseI (Promega) were added to digest the DNA template at 37°C for 30 min. The reaction was stopped with 5 μL 0.5 M EDTA.
Given concern for the possibility of nucleic acid exchange between wells during PAGE purification, we tested phenol/chloroformpurified sgRNAs side by side with PAGE-purified sgRNAs as indicated in Fig. 4 and Fig. S1A . Phenol/chloroform extraction was performed after addition of 190 μL RNA-free H 2 O. sgRNA was precipitated with 80 μL 3 M sodium acetate and 420 μL isoproponal and incubation at −20°C for 4 h. The RNA pellet was washed twice with 70% EtOH and once with 100% EtOH. The vacuum-dried pellet was reconstituted, and the sgRNAs refolded as described in In Vitro T7 Transcription of sgRNA with PAGE Purification.
Cas9 RNP Assembly and Electroporation. Cas9 RNP was prepared immediately before experiments by incubating 20 μM Cas9 with 20 μM sgRNA at a 1:1 ratio in 20 μM Hepes (pH 7.5), 150 mM KCl, 1 mM MgCl 2 , 10% glycerol, and 1 mM TCEP at 37°C for 10 min to a final concentration of 10 μM.
T cells were electroporated with a Neon transfection kit and device (Invitrogen). A total of 2.5 × 10 5 T cells was washed three times with PBS before resuspension in 8 μL of buffer T (Neon kit, Invitrogen). Cas9 RNP (2 μL of 10 μM Cas9 CTRL without sgRNA or 1-2 μL Cas9:sgRNA RNP; final concentration: 0.9-1.8 μM) and HDR template (0-200 pmol as indicated) were added to the cell suspension to a final volume of 11 μL (adjusted with Cas9 storage buffer) and mixed. Ten microliters of the suspension was electroporated with a Neon electroporation device (Invitrogen; 1,600 V, 10 ms, three pulses). The HDR templates for CXCR4 and PD-1 are single-stranded oligonucleotides complementary (-strand Q:2 ) to the target sequence and contain a HindIII restriction sequence along with 90-nt homology arms. Upon successful HDR, the respective PAM sites are deleted, which should prevent recutting of the edited site by the Cas9 RNPs. The PD-1 HDR template additionally causes a frameshift and nonsense mutation as early as amino acid position 25 by replacing 12 nt with 11 nt (CXCR4 HDR template: 5′-GGG CAA TGG ATT GGT CAT CCT GGT CAT GGG TTA CCA GAA GAA ACT GAG AAG CAT GAC GGA CAA GTA CAG GCT GCA CCT GTC AGT GGC CGA AAG CTT GGA TCC CAT CAC GCT TCC CTT CTG GGC AGT TGA TGC CGT GGC AAA CTG GTA CTT TGG GAA CTT CCT ATG CAA GGC AGT CCA TGT CAT CTA CAC AGT-3′; PD-1 HDR template: 5′-AAC CTG ACC TGG GAC AGT TTC CCT TCC GCT CAC CTC CGC CTG AGC AGT GGA GAA GGC GGC ACT CTG GTG GGG CTG CTC CAG GCA TGC AGA TAA TGA AAG CTT CTG GCC AGT CGT CTG GGC GGT GCT ACA ACT GGG CTG GCG GCC AGG ATG GTT CTT AGG TAG GTG GGG TCG GCG GTC AGG TGT CCC AGA GC-3′). The CXCR HDR control donor is a sequence scrambled version on the original CXCR4 HDR template containing a HindIII restriction site (CXCR4 control HDR template:  5′-TTC AAA ACT AGC GTC AGG GGC TCG ATT TAC TCG  GGA CTT GCT ACA ACA TCG CAG TCA CGC GCA CGA  TCC TTC CAG GAT TGG AGG TGG ACT TAG ATA AAG  CTT CCG TGT GCA CCG TAT AGA TTC GTT GAT GCA  GGC TAT TCC CGT GAT CCC ACG CGG AGG TGA TGG  AGC GTC AAG CAT AGC TAG CAC AGA TGA-3′) .
Electroporated T cells were transferred to 500 μL of their respective culture medium in a αCD3/CD28-coated 48-well plate. Plates were coated with 10 μg/mL αCD3 (UCHT1; BD Pharmingen) and αCD28 (CD28.2; BD Pharmingen) in PBS for at least 2 h at 37°C. Twenty-four hours after electroporation cells were resuspended and transferred to a noncoated well plate. Three to four days after electroporation, T cells were analyzed by FACS and T7 endonuclease I assay.
FACS Analysis of Edited T Cells. CXCR4 cell-surface staining was performed with αCXCR4-APC (12G5; BD Pharmingen) and αPD-1-PE (EH12.2H7; Biolegend) for 15 min on ice. Cells were kept at 4°C throughout the staining procedure until cell sorting to minimize antibody-mediated internalization and degradation of the antibody. Cells were sorted using a FACS Aria Illu (Becton Dickinson).
PCR Amplification of Target Region. A total of 5 × 10 4 to 2 × 10 5 cells were resuspended in 100 μL of Quick Extraction solution (Epicenter) was added to lyse the cells and extract the genomic DNA. The cell lysate was incubated at 65°C for 20 min and then at 95°C for 20 min and stored at −20°C. The concentration of genomic DNA was determined by NanoDrop (Thermo Scientific).
Genomic regions, containing the CXCR4 or PD-1 target sites, were PCR-amplified using the following primer sets: for CXCR4-forward 5′-AGA GGA GTT AGC CAA GAT GTG ACT TTG AAA CC-3′ and reverse 5′-GGA CAG GAT GAC AAT ACC AGG CAG GAT AAG GCC-3′ (938 bp); and for PD-1-forward 5′-GGG GCT CAT CCC ATC CTT AG-3′ and reverse 5′-GCC ACA GCA GTG AGC AGA GA-3′ (905 bp). Both primer sets were designed to avoid amplifying the HDR templates by annealing outside of the homology arms. The PCR contained 200 ng of genomic DNA and Kapa Hot start high-fidelity polymerase (Kapa Biosystems) in high GC buffer according to the manufacturer's protocol. The thermocycler setting consisted of one cycle of 95°C for 5 min, 35 cycles of 98°C for 20 s, 62°C for CXCR4 or 68°C for PD-1 for 15 s, and 72°C for 1 min, and 1 cycle of 72°C for 1 min. The PCR products were purified on 2% agarose gel containing SYBR Safe (Life Technologies). The PCR products were eluted from the agarose gel using QIAquick gel extraction kit (Qiagen). The concentration of PCR DNA was quantitated with a NanoDrop device (Thermo Scientific). A total of 200 ng of PCR DNA was used for T7 endonuclease I and HindIII analyses. For Fig. 1E , PCR product was cloned with TOPO Zero Blunt PCR Cloning Kit (Invitrogen) and submitted for Sanger sequencing. ] × 100, where a is the band intensity of DNA substrate and b and c are the cleavage products. For the quantification of the PD-1 T7E1 assay (Fig. 4D) , the intensity of the DNA substrate was calculated as the sum of the two large bands seen under all conditions. Calculation of the percentage of total edit based on T7E1 assays allows only an estimate of cleavage efficiency. 249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310   311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371 Fig . S1 . Effects of "on-target" and control HDR templates on PD-1 and CXCR4 surface expression levels. (A) The effects on CXCR4 expression were tested for two different HDR templates with the same nucleotide composition. In cells that were treated with CXCR4 Cas9 RNP, CXCR4 HDR template (dark red) was compared with a control HDR template consisting of the same nucleotides as the original CXCR4 HDR in randomized order including a HindIII restriction site (light red) and with no HDR template treatment (orange). Further controls are Cas9 CTRL (Cas9 without sgRNA; dark gray) and scrambled guide Cas9 RNP (no predicted cut within the human genome) with 100 pmol CXCR4 HDR template (light gray). The histograms show the results of four experiments with two differently in vitro-transcribed CXCR4 sgRNAs (two different purification strategies; Materials and Methods) tested in two different blood donors. As in Fig. 4 373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434   435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496 at the Bottom; scrambled guides were prepared for both experiments with phenol/chloroform extraction. (B) PD-1 (blue, Left) and CXCR4 (red, Right) surface expression levels after editing with the respective Cas9 RNPs and on-or off-target HDR templates. Targeted cells were compared with cells treated with Cas9 CTRL (dark gray) or scrambled guide Cas9 RNP (light gray).
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